We develop clinically effective, non-invasive, personal and connected medical devices for treatment and management of widespread diseases and medical conditions.

Our primary focus is on acute relief for certain types of pain.

Migraine Headaches

A migraine is a severe headache that might be preceded or accompanied by flashes of light (known also as “aura”), blind spots in vision, tingling in arms and legs, nausea, vomiting, and increased sensitivity to light and sound. Typically the headache affects one half of the head, is pulsating in nature, and lasts from 2 to 72 hours. Such migraine episodes seriously interfere with daily routine, degrading the individual quality of life.

The exact cause of migraines is still unknown. Migraine headaches are believed to be caused by changes in the brain-stem and its interactions with the trigeminal nerve – a major pain pathway, imbalances in brain chemicals, including serotonin, which helps regulate pain in the nervous system, genetics, or certain environmental factors.

Click here to learn more about the pathophysiology of migraine.

Migraine is the 3rd most prevalent disease in the world, affecting 38 million people in the US alone (including children) and around 1 billion worldwide.

Click here to read more about migraine.

What is DNIC/CPM?

Diffuse Noxious Inhibitory Controls (also known as Conditioned Pain Modulation – CPM) is a “pain inhibits pain” phenomenon in which the response to a pain stimulus is inhibited by a second pain stimulus due to engagement of descending inhibition from the brain-stem.

Click to read more about DNIC in this paper by JC Willer and D Le Bar

Measuring CPM

This filmed study, taken at the Rambam Health Campus, demonstrates the principles of Conditioned Pain Modulation (CPM):


Theranica’s Clinical Evidence

Theranica has completed two clinical studies of the Nerivio Migra, to date:

  1. A pilot study: An article describing the study and its results was published by the world’s popular Neurology magazine. Click here for more info. You can also read about the study in ClinicalTrials.gov.
  2. A pivotal study: TCH-003 is the largest study ever conducted to date of a device for the acute treatment of migraine, with 296 patients participating. It is a a prospective, randomized, double-blind,sham-controlled, multi-center study that evaluates the efficacy and safety of Nerivio Migra for the acute treatment of migraine. The study took place from January to September of 2018.
    Further information can be viewed here: TCH-003 info on ClinicalTrials.gov


Investigational Device. Limited by US Federal Law to Investigational Use Only in the United States
Exclusively for Clinical Investigation.